Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings

You may also be interested in...

Pfizer's Xalkori, Kyowa Hakko Kirin's Poteligeo And Others Receive Chuikyo Pricing

Kyowa Hakko Kirin's Poteligeo cleared for first global market launch, earning a 10% premium for added-value benefits.

Japan Considers Health Technology Assessments; Ponders Pharma Incentives

Japan’s Chuikyo is reviewing HTA systems in the UK, Germany, Australia and South Korea, but is also considering its own variation to reward industry compliance.

Japan Earnings Roundup: Astellas' Oncology Gains, Eisai Hit Hard, KHK Domestic Strength

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts